- Home
- OPEN vs IMNM Comparison
OPEN vs IMNM Comparison
Compare OPEN & IMNM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- OPEN
- IMNM
- Stock Information
- Founded
- OPEN 2014
- IMNM 2006
- Country
- OPEN United States
- IMNM United States
- Employees
- OPEN N/A
- IMNM N/A
- Industry
- OPEN Real Estate
- IMNM Medicinal Chemicals and Botanical Products
- Sector
- OPEN Finance
- IMNM Health Care
- Exchange
- OPEN Nasdaq
- IMNM Nasdaq
- Market Cap
- OPEN N/A
- IMNM 687.8M
- IPO Year
- OPEN N/A
- IMNM 2020
- Fundamental
- Price
- OPEN $0.87
- IMNM $7.71
- Analyst Decision
- OPEN Hold
- IMNM Strong Buy
- Analyst Count
- OPEN 5
- IMNM 5
- Target Price
- OPEN $1.70
- IMNM $26.40
- AVG Volume (30 Days)
- OPEN 56.9M
- IMNM 1.1M
- Earning Date
- OPEN 05-06-2025
- IMNM 05-16-2025
- Dividend Yield
- OPEN N/A
- IMNM N/A
- EPS Growth
- OPEN N/A
- IMNM N/A
- EPS
- OPEN N/A
- IMNM N/A
- Revenue
- OPEN $5,125,000,000.00
- IMNM $9,041,000.00
- Revenue This Year
- OPEN $3.84
- IMNM N/A
- Revenue Next Year
- OPEN $21.51
- IMNM $1,259.12
- P/E Ratio
- OPEN N/A
- IMNM N/A
- Revenue Growth
- OPEN 2.36
- IMNM N/A
- 52 Week Low
- OPEN $0.70
- IMNM $5.15
- 52 Week High
- OPEN $3.09
- IMNM $19.07
- Technical
- Relative Strength Index (RSI)
- OPEN 47.75
- IMNM 46.54
- Support Level
- OPEN $0.70
- IMNM $7.15
- Resistance Level
- OPEN $0.92
- IMNM $9.16
- Average True Range (ATR)
- OPEN 0.08
- IMNM 0.52
- MACD
- OPEN 0.01
- IMNM -0.05
- Stochastic Oscillator
- OPEN 46.49
- IMNM 27.86
About IMNM Immunome Inc.
Immunome Inc is a biopharmaceutical company. It is engaged in utilizing a proprietary human memory B cell platform to discover and develop first-in-class antibody therapeutics designed to change the way diseases are currently being treated. The objective of the company is to establish a broad pipeline of preclinical and clinical assets which it can efficiently develop through successive value inflection points. The company's primary focus areas are oncology and infectious diseases, including COVID-19. It operates in the U.S. Its current pipelines comprise IM-1021, a fibroblast activation protein (FAP), and others.